Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Study Number

3804823

Phase

III

Age Group

Adult

Principal Investigator

Ellis Levine

Purpose

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

Check your eligibility for this trial

Check now

Full Title

NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant
Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy
in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer
and an Oncotype Recurrence…

ClinicalTrials.Gov ID

NCT05879926

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.